2.1800 -0.13 (-5.63%)
Pre-Market: 5:50AM EST
|Bid||0.0000 x 2900|
|Ask||0.0000 x 2900|
|Day's Range||2.2400 - 2.5500|
|52 Week Range||0.9100 - 9.7800|
|Beta (5Y Monthly)||1.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.88|
It’s been a wild ride for GW Pharmaceuticals (NASDAQ:GWPH). Founded in 1998, it took 20 years for the cannabis-centered pharma firm to achieve its first FDA approval. That was for Sativex back in 2018, a sublingual spray consisting of a mixture of different cannabinoids, used to treat spasticity from multiple sclerosis. Later that same year, […] The post GW Deal With Jazz Spurs Pot Stock Wave, a Look at Smaller Players appeared first on Market Exclusive.
During Q3, Corbus Pharmaceuticals (NASDAQ:CRBP) brought in sales totaling $1.23 million. However, earnings decreased 10.92%, resulting in a loss of $33.97 million. Corbus Pharmaceuticals collected $286.35 thousand in revenue during Q2, but reported earnings showed a $38.14 million loss. Why ROCE Is Significant Changes in earnings and sales indicate shifts in Corbus Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Corbus Pharmaceuticals posted an ROCE of -1.16%. It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future. View more earnings on CRBP ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Corbus Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth. In Corbus Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions. Q3 Earnings Insight Corbus Pharmaceuticals reported Q3 earnings per share at $-0.43/share, which did not meet analyst predictions of $-0.42/share. See more from BenzingaClick here for options trades from Benzinga12 Health Care Stocks Moving In Monday's After-Market Session12 Health Care Stocks Moving In Wednesday's After-Market Session© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Inside the top performing stocks in the top ETF of January.